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Magnetic resonance imaging (MRI) of the breast gained a role in clinical practice thanks to 
the optimal sensitivity of contrast-enhanced (CE) protocols. This approach, first proposed 
30 years ago and further developed as bilateral highly spatially resolved dynamic study, 
is currently considered superior for cancer detection to any other technique. However, 
other directions than CE imaging have been explored. Apart from morphologic features 
on unenhanced T2-weighted images, two different non-contrast molecular approaches 
were mainly run in  vivo: proton MR spectroscopy (1H-MRS) and diffusion-weighted 
imaging (DWI). Both approaches have shown aspects of breast cancer (BC) hidden to 
CE-MRI: 1H-MRS allowed for evaluating the total choline peak (tCho) as a biomarker of 
malignancy; DWI showed that restricted diffusivity is correlated with high cellularity and 
tumor aggressiveness. Secondary evidence on the two approaches is now available 
from systematic reviews and meta-analyses, mainly considered in this article: pooled 
sensitivity ranged 71–74% for 1H-MRS and 84–91% for DWI; specificity 78–88% and 
75–84%, respectively. Interesting research perspectives are opened for both techniques, 
including multivoxel MRS and statistical strategies for classification of MR spectra as well 
as diffusion tensor imaging and intravoxel incoherent motion for DWI. However, when 
looking at a clinical perspective, while MRS remained a research tool with important 
limitations, such as relatively long acquisition times, frequent low quality spectra, difficult 
standardization, and quantification of tCho tissue concentration, DWI has been inte-
grated in the standard clinical protocols of breast MRI and several studies showed its 
potential value as a stand-alone approach for BC detection.
Keywords: breast cancer, diffusion-weighted imaging, magnetic resonance imaging, proton MR spectroscopy, 
systematic reviews and meta-analyses
inTRODUCTiOn
Valuable results of breast magnetic resonance imaging (MRI) were first obtained 30 years ago, when 
sequences acquired after intravenous injection of a Gd-chelate as a contrast material were added 
to a non-contrast protocol (1). This approach was further developed as bilateral highly spatially 
resolved contrast-enhanced (CE) dynamic study, which is now currently considered superior for 
breast cancer (BC) detection to any other imaging technique with a reported pooled sensitivity and 
specificity of 93.2 and 71.1%, respectively (2), as also shown by studies on MRI screening of women at 
increased risk of BC (3–6). In fact, CE-MRI provides a physiopathological information that correlates 
TaBle 1 | Diagnostic performance of proton MR spectroscopy and Dwi of the breast as evaluated in systematic reviews and meta-analyses published 
between 2010 and 2015.
included  
studies
lesions/
patients
Pooled sensitivity Pooled specificity notes Reference
Point  
estimate (%)
95% Ci Point  
estimate (%)
95% Ci
Proton MR spectroscopy (1H-MRS)
19 1198/1183 73 64–82 88 85–91 tCho evaluation: visual, SNR, 2 or 4 cutoff values (34)
18 1169/NR 71 68–74 85 81–88 tCho evaluation: visual, SNR, variable cutoff values (35)
16 1049/NR 74 70–77 78 73–82 tCho evaluation: visual, SNR, variable cutoff values (36)
10 792/NR 74 69–77 76 71–81 tCho evaluation: SNR, 2 cut off (37)
Diffusion-weighted imaging (Dwi)
13 964/815 84 82–87 79 75–82 Heterogeneity among individual studies; subgroup analysis (50)
14 1276/1140 86 80–91 76 67–83 Heterogeneity among individual studies; subgroup analysis (2)
26 2151/2111 91 84–95 75 61–85 Including 11 studies using b values ≤600 mm2/s (51)
26 2151/2111 89 85–92 84 78–89 Including 30 studies using b values >600 mm2/s (51)
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with increased vascularity, vascular permeability, and interstitial 
space in malignant tissue, not available from mammography and 
ultrasound. This diagnostic modality has been shown to provide 
even better sensitivity for BC detection than new techniques 
such as digital breast tomosynthesis (7–9). As a consequence, 
CE-MRI has been recommended for a spectrum of indications 
by medical bodies such as the American College of Radiology 
(10), the European Society of Breast Imaging (11, 12), and the 
European Society of Breast Cancer Specialists (EUSOMA) (13). 
The debate is still open on preoperative MRI (14, 15), but new 
indications, such as nipple discharge (16, 17) and evaluation of 
lesions with uncertain malignant potential (so-called B3 lesions), 
are emerging (18).
However, MR directions other than dynamic CE imaging 
have been explored searching for a better specificity and a deeper 
insight into BC biology and metabolism, opening a wider and 
wider window for the so-called non-contrast breast MR. Of note, 
the clinical relevance of a non-contrast approach for breast MR 
has been recently fueled by the evidence of Gd accumulation 
in the brain after multiple administrations of contrast material 
(19, 20), which implies a word of caution for the use of Gd-based 
contrast at least in the case of screening of healthy subjects when 
the risk profile is not high.
Traditionally, unenhanced sequences were associated to CE 
sequences in a breast MRI protocol for the sake of appraising 
morphologic features for lesion characterization. Several signs, 
typically appreciated on T2-weighted images, can be associated 
with malignancy, the most important being peritumoral and 
prepectoral edema (21), hook sign, i.e., a hook-like spiculated 
dendrite from the lesion to the pectoral muscle (22), and necrosis 
sign, i.e., a hyperintense center in a hypointense lesion (23). Non-
enhancing septations are instead usually associated with benign 
lesions such as fibroadenomas (24).
Two other non-contrast MR methods were mainly imple-
mented for an in vivo study of breast tissues: proton MR spec-
troscopy (1H-MRS) and diffusion-weighted imaging (DWI).
Proton MR spectroscopy is a non-invasive technique assess-
ing biochemical tissue properties. The presence of a resonance 
at 3.14–3.34  ppm, attributed to choline metabolites, such as 
free choline, phosphocholine, and glycerophosphocholine, is 
usually reported as total choline (tCho). An increased tCho has 
been detected in malignant breast lesions (25–31), as a result of 
complex metabolic alteration of biosynthetic and/or catabolic 
phosphatidylcholine-cycle pathways: the de novo biosynthesis of 
phosphatidylcholine via the Kennedy pathway and three different 
major catabolic pathways, contributing to phosphocholine and/
or tCho accumulation (31).
The other non-contrast approach – DWI – is a way for 
characterizing tissue properties on the basis of the difference 
in the movement freedom of water molecules (diffusion) along 
multiple spatial directions, quantified via the measurement of 
the mean diffusivity and the apparent diffusion coefficient (ADC) 
(32). Breast malignant tissues show restricted diffusion and sig-
nificantly lower ADC values compared with those of normal and 
benign breast tissues (33).
Many studies were published regarding clinical breast applica-
tions of MRS and DWI showing a potential for both techniques. 
The aim of this review is to look at secondary evidence, published 
between 2010 and 2015, on 1H-MRS and DWI of the breast as 
well as to try to define which of the two techniques is clinically 
emerging as a routine tool added to CE-MRI or also potentially 
usable as a stand-alone approach for cancer detection.
DiaGnOSTiC PeRFORManCe OF 1H-MRS
The diagnostic performance of 1H-MRS of the breast, performed 
using the single-voxel technique, was evaluated by four systematic 
reviews (34–37) (Table 1).
The pooled sensitivity ranged between 71 and 74%, and the 
pooled specificity between 78 and 88%. Baltzer and Dietzel also 
performed a subgroup analysis for mass and non-mass lesions 
on six studies obtaining a pooled sensitivity of 68 and 62%, and 
a pooled specificity of 88 and 69%, respectively (34), showing 
that especially for non-mass lesions, 1H-MRS has a too low 
diagnostic performance to be used in clinical practice. Another 
subgroup analysis was performed on seven studies by Wang et al. 
(37), showing that the area under the curve (AUC) at receiver 
operating characteristic (ROC) analysis was higher (92 vs. 89%) 
when tCho signal-to-noise ratio ≥2 was selected as a cutoff for 
malignancy.
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All studies included in this meta-analysis (37) showed a 
high heterogeneity for both sensitivity and specificity, prob-
ably due to the large variety of MRS techniques and different 
field strengths used. Even though improvements from newer 
technology (such as 3-T magnets and multiple radiofrequency 
sources) were expected, the authors (37) concluded that none 
of these innovations significantly influenced the diagnostic 
performance, as year of publication showed no effect on the 
diagnostic performance.
Notably, small masses (between 5 and 10  mm in diameter) 
or foci (<5  mm in diameter) are commonly encountered on 
CE-MRI, depending on the clinical setting, a proportion of them 
turning out to be false positives. As a consequence, to avoid 
work-up (targeted ultrasound, needle biopsy) would be a great 
achievement. However, in this regard, 1H-MRS is scarcely useful. 
The large majority of studies did not include lesions smaller than 
10 mm, thus limiting the applicability of 1H-MRS for characteri-
zation of small lesions and early BC diagnosis.
One relevant technical problem for 1H-MRS, especially 
important for small lesions, is the need for patient’s immobility 
during the acquisition, i.e., for 5–10  min or more (depending 
also on the time for the preliminary optimization checks), which 
also impacts on patient’s throughput and cost-effectiveness. Of 
note, a trend for a higher sensitivity of 1H-MRS was observed 
when acquisition is performed before contrast injection, due to 
a detrimental effect of ionic-charged contrast materials in both 
experimental and clinical settings (38). As lesion localization (the 
placement of the spectroscopic volume of interest) has to be made 
on CE images (especially for otherwise not visible small lesions), 
the majority of 1H-MRS studies were performed after contrast 
injection, potentially implying a suboptimal sensitivity. On the 
other hand, a major clinical application of 1H-MRS should be 
lesion characterization, typically arising immediately after the 
detection, implying that 1H-MRS should be performed immedi-
ately after CE-MRI, which usually lasts about 15–20 min. Thus, a 
time prolongation of additional 10 min increases the probability 
of patient’s movements, reducing the possibility of getting good 
quality spectra.
Moreover, again especially important for small lesions, to 
adapt the volume of interest to the lesion morphology is often not 
easy: cubic or anyway squared volumes of interest tend to include 
tissues (fat or gland) surrounding the lesion, determining volume 
contamination and resulting in reduced sensitivity (28). Lesion 
located posteriorly, close to the pectoral muscle or the thoracic 
wall, or superficially, near the skin, may provide spectra with low 
signal-to-noise ratio. Thus, even using 3-T magnets and multiple 
radiofrequency sources, in clinical practice about 20% of lesions 
finally result to be not evaluable with MRS (39).
Several of these limitations are not acting when 1H-MRS is 
applied for the evaluation of the response to neoadjuvant therapy 
(NAT), typically administered to patients with locally advanced 
BCs. Studies have shown that 1H-MRS enables an early predic-
tion of the final NAT effect (40–42). This is, in our opinion, the 
most promising clinical application of 1H-MRS, even though it 
regards a relatively small fraction of patients. However, also in 
this field, as we will explain below, DWI is a strong competitor 
(Figure  1). Anyway, for a well-accepted application of MRS 
techniques to the NAT setting, large multicenter studies using 
clearly standardized pathologic response classification are war-
ranted (43–46).
Finally, we should note that 1H-MRS was mostly applied 
in clinical breast studies using methods not allowing for 
quantification of tissue tCho concentration. Both the SNR 
between tCho peak and noise (usually with a ≥2 threshold for 
malignancy) (34–37) and the integral under the tCho peak 
(30) have limitations and low potential for standardization. 
On the other hand, tissue tCho quantification using internal 
or external standard of reference (47) implies dedicated high 
technical expertise. This highlights the need for cooperation 
with a physicist experienced in MRS, not only for tCho tissue 
quantification but also generally if MRS has to be integrated in 
a clinical setting. This is a possibility that only large hospitals 
or academic facilities can afford and is another limitation for 
MRS effectiveness.
Highly interesting results were obtained, even at 1.5  T, by 
Stanwell et al. (48), carefully referencing the spectra using a spe-
cial post-processing: 80% sensitivity and 100% specificity. They 
optimized spectral resolution from human breast tissues resolv-
ing the composite choline resonances of the tCho peak. False 
positives including three lactating women were distinguished by 
a resonance at 3.28 in contrast with the profile from BC patients 
consistent with phosphocholine centered at 3.22 ppm. However, 
a false negative rate of 20% remained unresolved, and this high 
spectral resolution was never reproduced, not even using 3-T 
magnets.
Looking at the potential prognostic value of 1H-MRS of the 
breast, it is worth to note that tCho levels, evaluated by 1H-MRS, 
were significantly higher for invasive ductal carcinoma, for 
cancers with high nuclear or histologic grade, and ER-negative 
and triple-negative status (49). This perspective deserves confir-
mation in future large studies with quantification of tissue tCho 
concentration.
DiaGnOSTiC PeRFORManCe OF Dwi
Breast MR sequences for DWI have been mainly used to try to 
characterize breast lesions, adding a new parameter in the algo-
rithm for diagnosis, with the potential for avoiding unnecessary 
biopsy, especially for MRI-only visible lesions that should be 
sampled under MR-guidance, a time-demanding and high-cost 
procedure (11).
Studies were performed in order to understand the potential 
value of DWI added to CE-MRI. Two meta-analyses, from 
Chen et al. (50) and from Zhang et al. (2), reported an overall 
sensitivity of 84 and 86% and an overall specificity of 79 and 76%, 
respectively. However, a notable heterogeneity among individual 
studies was observed, and a subgroup analysis to investigate 
the source of this heterogeneity was performed. The two most 
important factors resulted to be the b value of diffusion gradient 
used and the so-called threshold effect (a detectable difference in 
sensitivities and specificities due to different thresholds used in 
included studies).
Different b values significantly affect the ADC of breast lesions 
and therefore confound quantitative DWI. In a large systematic 
FiGURe 1 | 1H-MRS and Dwi for evaluating the response to neoadjuvant therapy (naT) of a locally advanced breast cancer. A 37-year-old woman with 
locally advanced breast cancer before, during, and after neoadjuvant therapy (NAT). Before treatment, the lesion at the lower external quadrant of the left breast is 
well depicted as a 34.4-mm nodule on subtracted CE-MRI with 0.1 mmol/kg of gadobenate dimeglumine (a), shows a high tCho peak at 1H-MRS with a 
signal-to-noise ratio (SNR) of 6.7 (B), low diffusivity as a high signal on DWI (C), and a low (0.776 × 10−3 mm2/s) mean ADC value (D). After two NAT cycles, the 
lesion is reduced in size (28.7 mm) at CE-MRI (e), while the tCho peak is no longer detectable at 1H-MRS (F); DWI (G) and ADC map (H) show an evident 
increased diffusivity (mean ADC 1.559 × 10−3 mm2/s). After the end of treatment, the lesion is not visible at all on CE-MRI (i), DWI (J), and ADC map (K); therefore, 
MRS was not performed. The lesion was a metaplastic carcinoma with condroid differentiation (negative for estrogen, progesterone, and HER2 receptors, Ki67 
80%), and after surgical removal, a complete pathological response was appreciated. Both 1H-MRS and DWI early predicted the pathological response to NAT 
showing an effect more pronounced than that of CE-MRI. Acquisition times: CE-MRI 9 min; 1H-MRS 8 min (including preparation); DWI 5 min (Philips Achieva STx 
3.0 T, MultiTransmit radiofrequency technology; dedicated 16-channel breast coil; Azienda Ospedaliera Universitaria Integrata, Verona, Italy).
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review performed on 26 studies, including a total of 2111 patients 
with 2151 breast lesions, Dorrius et al. (51) showed that the com-
bination of b = 0 and 1000 s/mm2 is optimal for benign/malignant 
differentiation. Pooled 89% sensitivity and 84% specificity were 
reported for b values >600 s/mm2 (ROC-AUC 0.93), while using 
b values ≤600 s/mm2, 91% sensitivity and 75% specificity were 
obtained (ROC-AUC 0.92). A summary of the recently published 
meta-analyses on breast DWI is reported in Table 1.
There is no clear consensus regarding the threshold values for 
ADC to diagnose malignancy. A substantial variability of thresh-
old values, ranging 0.90–1.76 × 10−3 mm2/s has been observed 
(51). As a recommendation, a relatively higher threshold value 
may be used to minimize missing malignancy.
Of note, the studies evaluating mass lesions had a higher 
specificity (84%) than those evaluating non-mass lesions 
(70%) (2). When added to CE-MRI, DWI sequences showed 
a significant diagnostic gain: the summary ROC-AUC of 
CE-MRI combined with DWI was 0.94 compared with 0.85 for 
CE-MRI alone (2). Differently from 1H-MRS, contrast injec-
tion does not negatively impact on DWI performance (51); 
ADC measures were reported to not significantly change fol-
lowing DCE-MRI at 3 T, suggesting that DWI and DCE-MRI 
can be performed in any order without affecting diagnostic 
performance (52). Moreover, Janka et  al. showed that DWI 
after contrast injection even leads to a slightly better benign/
malignant discrimination (53).
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Furthermore, DWI sequences are not dependent on CE-MRI. 
They can be performed without previous knowledge of lesion 
location, as the DWI field of view includes both breasts with a 
4- to 5-min acquisition time.
Interestingly, some authors showed as DWI could be used 
as the main component of an unenhanced (non-contrast) MRI 
examinations with good sensitivity and high specificity, at least if 
we consider mass lesions. A reduced detection rate of small mass 
lesions and of non-mass lesions has to be taken into account (54, 
55). However, a sensitivity theoretically comparable with that of 
screening mammography (54) as well as a potential for avoiding 
the double reading (55) candidate DWI as a sequence to be used 
for explorative non-contrast MRI screening studies.
Notably, DWI sequences are undergoing a progressive 
technical refinement. Spatial resolution and image quality are 
increasing, allowing also for a more detailed morphology evalu-
ation (56, 57). As a matter of fact, authors have positively tried to 
integrate information coming from DWI into the Breast Imaging 
Reporting and Data System BI-RADS (58).
Considering the potential prognostic value of DWI, we finally 
highlight that a recent systematic review demonstrated that breast 
lesions with increased signal intensity on DWI and decreased 
signals on ADC are more likely associated to lymph-nodal 
metastases (59).
ReSeaRCH TRenDS FOR 1H-MRS  
anD Dwi OF THe BReaST
First of all, authors attempted to integrate CE-MRI, 1H-MRS, 
and DWI (multiparametric MRI, mpMRI) to yield significantly 
higher ROC-AUC (0.936) in comparison with just two of them 
(0.808) (60). Positron emission tomography (PET) was also 
added to provide an intriguing mpMRI/PET approach for lesion 
characterization (61), but we cannot propose this high-cost 
approach for characterization of breast lesions, when most cases 
can be solved by a needle sampling.
Regarding 1H-MRS, two interesting topics are multivoxel 
spectroscopy and statistical strategies for classifying MR spec-
tra. Multivoxel 1H-MRS should overcome the need of a  priori 
knowledge of lesion location (62), allowing for BC screening (or 
for stratifying BC risk) on the basis of tCho levels in the healthy 
gland tissue. However, multivoxel 1H-MRS is more technically 
challenging than single-voxel 1H-MRS for shimming and fat 
suppression (63). Statistical strategies for classification of spectra 
were proposed in a 2D correlated spectroscopy (COSY), where 
the composite resonances are separated by the use of a second 
frequency (63). However, this interesting approach seems to be 
not easy to be reproduced for clinical practice.
Finally, also 31P-MRS (64) was used to provide a direct 
method for the in  vivo detection and quantification of endog-
enous biomarkers, yielding a new intriguing method for the 
non-invasive assessment of prognostic and predictive biomarkers 
in BC treatment.
Regarding DWI, several studies have shown that important 
information is lost when one relies just on the average ADC and 
that a higher sensitivity is given by minimum ADC instead of any 
metrics of the central tendency of ADC values distribution. Mori 
et al. (65) indicated that a minimum ADC value <1.1 × 10−3 mm2/s 
and that an ADC difference (maximum minus minimum ADC) 
greater than 0.23 × 10−3 mm2/s suggests the presence of invasive 
carcinoma in cases with only DCIS at biopsy, a crucial informa-
tion for patient management.
Second, studies explored the possibility of characterizing 
axillary lymph nodes using DWI in BC patients. One study 
(66) considered only nodes with metastases ≥5 mm, obtaining 
95% sensitivity and 92% specificity. More recent studies (67–69) 
obtained sensitivities from 72 to 85% and specificities from 80 to 
88%. Future multidisciplinary researches should be placed in the 
context of the current rethinking of axillary dissection (70).
However, the most intriguing research areas for breast DWI are 
diffusion tensor imaging (DTI) and intravoxel incoherent motion 
(IVIM). For DTI (which adds information about tissue micro-
structure by addressing diffusion spatial direction), at least six 
DWI gradient directions should be applied, so that a symmetrical 
matrix, the diffusion tensor indeed, can be calculated, describing 
the anisotropic water diffusion in the tissue. Fractional anisotropy 
(FA) describes diffusion anisotropy quantitatively on a range from 
1 (maximum anisotropy) to 0 (isotropy) (71). Experiences on 
breast DTI showed that FA does not have incremental value for 
differential diagnosis over ADC values (71). Eyal et al. (72) devel-
oped a breast DTI protocol at 3 T and image processing means for 
obtaining vector and parametric maps of the water diffusion ten-
sor. Evaluation of the various diffusion parametric maps indicated 
that the prime diffusion coefficient and the maximal anisotropy 
are the most efficient parameters for detecting and diagnosing BC. 
So far, DTI turned out to be a great tool for visualizing the breast 
parenchyma but its clinical application remains to be investigated.
The IVIM quantifies molecular diffusion more accurately than 
ADC and provides additional information on microperfusion tis-
sue properties. It separates the contribution of T2 from diffusivity 
using multiple b values, hence being less dependent on the choice 
of individual b values (73). However, IVIM as well as DTI imply 
longer acquisition times, and these techniques are not currently 
suitable for a large use in clinical practice.
COnClUSiOn
The results coming from the secondary evidence about 1H-MRS 
and DWI of the breast are clearly in favor of an easier and more 
effective use of DWI. If one of the two approaches for non-contrast 
breast MR has to be chosen for clinical practice, DWI is certainly 
the winner.
When looking at a clinical perspective, while 1H-MRS 
remained a tool with relevant limitations such as relatively 
long acquisition times, frequent low quality spectra, difficult 
standardization and quantification  of tissue tCho concentration, 
DWI is feasible in almost all cases and adds diagnostic power to 
CE-MRI. Moreover, seminal studies showed the potential value 
of DWI as a stand-alone approach for BC detection.
As matter of fact, in the context of an ongoing international 
multicenter study exploring the value of preoperative CE-MRI 
with over 4500 patients enrolled so far (15), 84% of them were 
studied using a technical protocol including DWI among the 
standard sequences.
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